ABSTRACT

The effective creation of transdermal treatments for Parkinson's disease has long been a problem for the medical profession. However, recent advancements in the field, particularly with the use of rotigotine, have sparked hope for more breakthroughs in the future. Despite its potential, it offers slow and sustained drug delivery over extended periods. Nevertheless, transdermal drug delivery holds great promise as it offers a more consistent and steady release of medication, which can help control symptoms and reduce side effects. There has been a recent focus on improving delivery methods, as well as the stability of the medication upon delivery. These efforts have yielded promising results, with patches and gels that deliver rotigotine, apomorphine, and carbidopa/levodopa currently in clinical trials. In addition, ongoing research into new technologies like microneedles, nanoparticles, and gene therapy have the potential to improve the efficacy and safety of these treatments. The development of transdermal-based formulations for Parkinson's disease is still in the clinical trial phase and is yet to be approved by regulatory agencies like the FDA. The regulatory landscape for transdermal drug delivery is complex and requires compliance with relevant regulatory agencies' guidelines to bring these products to market. The future scope of transdermal drugdelivery for Parkinson's disease treatment is promising, with the potential for more long-term treatment options that can delivers genetic material to cells in the brain to produce a specific protein that is lacking in Parkinson's disease. Keywords: Transdermal drug delivery, Parkinson's disease treatment, Blood-brain barrier, Controlled-release technology, Patient compliance
Publication date: 01/03/2024

https://ijbpas.com/pdf/2024/March/MS_IJBPAS_2024_7856.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.3.7856